Cervical cancer has become an important disease that jeopardizes women's health, causing hundreds of thousands of new cases annually. Human papillomavirus (HPV) is the leading cause for cervical cancer. Since the world's first HPV vaccine was licensed in 2006, 92 countries around the world have introduced them in national immunization programs. The WHO recommends that scientific economic evaluation should be achieved before the introduction, but this is more difficult for low-and middle-income countries. Therefore, this article introduces a mathematical model recommended by WHO in 2014 to quickly and easily accomplish economic evaluation of HPV vaccine -the PRIME, and take the China's 2018 data published by International Agency for Research on Cancer (IARC) as an example. The evaluation result shows that the introduction of HPV vaccine in Chinese 12-year-old women is cost-effective.
宫颈癌已成为危害女性健康的重要疾病，每年导致数十万新发病例，人乳头瘤病毒（HPV）是导致宫颈癌的主要原因。自2006年全球首个HPV疫苗上市以来，世界范围内已有92个国家将HPV疫苗纳入到国家免疫规划中。WHO建议将宫颈癌疫苗纳入到免疫规划之前需进行科学的卫生经济学评估，但这对中低收入国家而言较为困难。因此本文介绍WHO在2014年推荐的一款能够快速、简便的进行HPV疫苗卫生经济学评价的数学模型——人乳头瘤病毒疫苗建模与经济学评估快速界面（PRIME），并以国际癌症研究所（IARC）公布的中国2018年数据为例进行实例分析。评价结果显示，在中国12岁女性中引入HPV疫苗具有较好的成本效果。.
Keywords: Economics; Human papillomavirus; PRIME; Uterine cervical neoplasms; Vaccines.